Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention

Cardiovascular Revascularization Medicine

Volumn 12, Issue 2, 2011, Pages 90-93

  Patel, Kalpesh ^a,b   King, Christopher A ^a,b   Jovin, Ion S ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Cardiac catheterization; Contrast induced nephropathy; Coronary angiography; Percutaneous coronary intervention

Indexed keywords

CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIOCARDIOGRAPHY; CARDIAC PATIENT; COMORBIDITY; CONTRAST INDUCED NEPHROPATHY; HEART CATHETERIZATION; HUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIAC CATHETERIZATION; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; HUMANS; KIDNEY DISEASES; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952711436     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2010.01.002     Document Type: Review

References (21)

1. Barrett BJ, Parfrey PS Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006, 354(4):379-386.
2. Pucelikova T, Dangas G, Mehran R Contrast-induced nephropathy. Catheter Cardiovasc Interv 2008, 71:62-72.
3. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008, 40:749-755.
4. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103(5):368-375.
5. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A, Russell RO, Ryan TJ, Smith SC ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999, 33(6):1756-1824.
6. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004, 44:1393.
7. McCullough PA, Bertrand ME, Brinker JA, Stacul F A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006, 48:692-699.
8. Solomon R, Werner C, Mann D, D'Elia J, Silva P Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994, 331:1416-1420.
9. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184.
10. 1: a randomized, double-blind, placebo-controlled study. Am J Ther 2001, 8:155-162.
11. Hoogwerf BJ, Young JB The HOPE study - effect of ramipril on cardiovascular risk in those with known atherosclerosis or diabetes. Cleve Clin J Med 2000, 67(4):287-293.
12. Persson PB, Hansell P, Liss P Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005, 68:14-22.
13. Xiong X, Jia R, Yang D, Ding G Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis. Pharmacol Res 2006, 54:253-260.
14. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995, 6:1451-1458.
15. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999, 51:521-526.
16. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehren R Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005, 95:13-19.
17. Hölscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H Predictors for contrast-induced nephropathy and long-term survival: prospectively assessed data from the Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol 2008, 24:1-6.
18. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 2003, 3(2):104-106.
19. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006, 104:20-27.
20. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001, 104:1985-1991.
21. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Matthew V, Garratt KN, Holmes DR Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259.